AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 9 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A growing body of evidence continues to point to transduced dendritic cells as important adjuvants for tumor vaccines.
"Gene delivery to dendritic cells provides an intracellular source of antigen for efficient and persistent loading to MHC class I molecules capable of activating CD8[superscript]+ CTLs, which play a central role in antitumor immunity," N. Okada and colleagues, Kyoto Pharmaceutical University, Japan, described in a recent report.
To date, attempts at efficient dendritic cell transduction have met with many failures and some successes. Okada and colleagues have performed research suggesting the fiber-mutant adenovirus vector encoding for the Arg-Gly-Asp (AD-RGD) sequence in the HI loop is a reliable vector for efficient gene delivery to dendritic cells (DC).
"We compared immunological properties and vaccine efficacy of DC2.4 cells, an immature murine DC line, transduced with an ovalbumin (OVA) gene by fiber-mutant Ad (Ad-RGD-OVA) or conventional Ad (Ad-OVA)," the group said in Cancer Research.
Vector comparisons indicated DC cells infected with Ad-RGD-OVA were better for presenting OVA peptides than the control cells were. Furthermore, AD-RGD-OVA was better at inducing peptide-specific CTL response, Okada and coworkers said.
"Vaccination with Ad-RGD-OVA infected DC2.4 cells could achieve an equal or greater antitumor effect against challenge with ...
Source: HighBeam Research, Transduced Dendritic Cells Inspire Antitumor Effect.(Brief Article)